Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/10/2025 | $34.00 | Market Perform → Outperform | BMO Capital Markets |
| 4/30/2024 | $19.00 | Buy | Guggenheim |
| 6/17/2022 | $7.00 | Outperform | BMO Capital Markets |
| 6/9/2022 | Outperform → Mkt Perform | William Blair | |
| 9/10/2021 | $23.00 → $26.00 | Buy | Stifel |
4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)
4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)
4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)
BMO Capital Markets upgraded Precision BioSciences from Market Perform to Outperform and set a new price target of $34.00
Guggenheim initiated coverage of Precision BioSciences with a rating of Buy and set a new price target of $19.00
BMO Capital Markets initiated coverage of Precision BioSciences with a rating of Outperform and set a new price target of $7.00
Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies, including gene elimination, gene insertion, and gene excision programs, today announced that it will publish financial results for the fourth quarter and fiscal year 2024 and provide a business update on March 26, 2025. About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical stage gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. Key
Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, today announced that it will publish financial results for the third quarter 2024 and provide a business update on November 4, 2024. About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical stage gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. Key capabilities and differentiating characteristics may enab
Precision BioSciences, Inc. (NASDAQ:DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies, today announced that it will publish financial results for the second quarter 2024 and provide a business update on August 1, 2024. About Precision BioSciences, Inc. Precision BioSciences, Inc. is an advanced gene editing company dedicated to improving life (DTIL) with its novel and proprietary ARCUS® genome editing platform that differs from other technologies in the way it cuts, its smaller size, and its simpler structure. Key capabilities and differentiating characteristics may enable ARCUS nucleases to drive more inten
4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)
4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)
4 - PRECISION BIOSCIENCES INC (0001357874) (Issuer)
Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for diseases with high unmet need, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for PBGENE-HBV, the Company's lead wholly owned in vivo gene editing program designed to cure chronic hepatitis B by eliminating cccDNA, the key source of replicating hepatitis B virus (HBV), and inactivating integrated HBV DNA in hepatocytes. "We are pleased to receive Fast Track designation from the FDA for PBGENE-HBV and believe this classification underscores the urgent need for improv
Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies, including gene elimination, gene insertion, and gene excision programs, today announced that management will present at the 24th Annual Needham Virtual Healthcare Conference taking place on April 7, 2025. Presentation Details: Date: Monday, April 7, 2025 Time: 3:00 PM ET in Track 2 Format: Presentation Webcast Registration: Link A live webcast will also be accessible on Precision's website in the Investors section under Events & Presentations at investor.precisionbiosciences.com. An archived replay of the webcasts will
- Announced first in vivo clinical validation for ARCUS gene editing across two distinct programs including wholly owned PBGENE-HBV and partnered program ECUR-506 - - Commenced Phase 1 ELIMINATE-B clinical trial for PBGENE-HBV, the first gene editing technology studied for Hepatitis B, in fourth quarter of 2024 - - Demonstrated PGENE-HBV was safe and well tolerated with substantial antiviral activity measured by reduction of Hepatitis B surface antigen after only one administration at lowest dose level; Subsequent doses of PBGENE-HBV to follow with data expected throughout 2025 - - Announced complete clinical response in first infant dosed by partner iECURE in ongoing Phase 1/2 clinical
SCHEDULE 13G/A - PRECISION BIOSCIENCES INC (0001357874) (Subject)
DEFA14A - PRECISION BIOSCIENCES INC (0001357874) (Filer)
DEF 14A - PRECISION BIOSCIENCES INC (0001357874) (Filer)
SC 13G/A - PRECISION BIOSCIENCES INC (0001357874) (Subject)
SC 13G/A - PRECISION BIOSCIENCES INC (0001357874) (Subject)
SC 13G/A - PRECISION BIOSCIENCES INC (0001357874) (Subject)
- Wholly owned programs PBGENE-HBV for Chronic Hepatitis B virus and PBGENE-PMM for m.3243 mitochondrial disease on track for IND and/or CTA submissions in 2024 and 2025, respectively - Expanded Hepatitis Scientific Advisory Board with addition of world-class clinical investigators Mark Sulkowski, M.D. and Jordan Feld, M.D., M.P.H. - Sufficient capital to realize Phase 1 clinical data for multiple in vivo gene editing programs; Expected cash runway into the second half of 2026 - Regained control of three advanced preclinical programs for development internally or with partners, including a novel gene editing approach for Duchenne Muscular Dystrophy Precision BioSciences, Inc. (NASDA
Precision BioSciences, Inc. (NASDAQ:DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits, including gene elimination, insertion, and excision, today announced the appointment of Mark Sulkowski, M.D. and Jordan Feld, M.D., M.P.H. to its Hepatitis Scientific Advisory Board (SAB). Dr. Sulkowski and Dr. Feld will join Raymond Schinazi, Ph.D., DSc, inaugural member of Precision's Hepatitis SAB, to provide counsel and deepen the Company's scientific and clinical expertise ahead of Precision's anticipated Investigational New Drug (IND) and/or Clinical Trial Application (CTA) submission of PBGE
New Director Brings Proven Financial and Leadership Experience Fifth Director Added to the Board of Directors Since April 2021 Precision BioSciences, Inc. (NASDAQ:DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that Melinda Brown has been appointed as a Director on the Company's Board of Directors and Chair of the Board's Audit Committee. Ms. Brown is a financial expert with proven experience leading accounting, finance and enterprise risk management teams in large, public companies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/202